From the therapeutic perspective, a high correlation of HMGA2 with metastasis in poor prognostic cancers including RB may support its potential application as a biomarker in the blood or possibly aqueous humor since detection of HMGA2 mRNA in peripheral blood samples of patients with metastatic breast cancers has presented a reasonable expectation of success in other cancers (Langelotz et al., 2003). This evidence concerns the gene HMGA2 and retinoblastoma.